OSMOTICA PHARM US
PharmaOSMOTICA PHARM US is a pharmaceutical company focused on Cardiovascular, Neurology. Key products include RELEXXII.
OSMOTICA PHARM US's Key Drugs
OSMOTICA PHARM US's core commercial portfolio centers on RELEXXII, spanning Cardiovascular and Neurology — its most strategically important drugs approved in the last 15 years.
OSMOTICA PHARM US's Recent FDA Approvals
New NDA/BLA approvals for OSMOTICA PHARM US over the last two years — novel drugs only, excluding generics and label supplements.
OSMOTICA PHARM US's Therapeutic Areas
OSMOTICA PHARM US's approved drugs and pipeline span 2 therapeutic areas, led by Cardiovascular and Neurology, across 0 biologic and 1 small-molecule drug. Weighted by commercial stage — approved drugs count most, then late-stage trials.
OSMOTICA PHARM US's Top Competitors
OSMOTICA PHARM US's closest competitors by therapeutic-area and drug-target overlap include GE HEALTHCARE, Novo Nordisk, and LEDERLE. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
OSMOTICA PHARM US Pipeline Snapshot
Active clinical trials for OSMOTICA PHARM US across all therapeutic areas, from ClinicalTrials.gov.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • RELEXXII leads revenue
- • Drug-level revenue analysis
Trial Catalysts
- • Cardiovascular pipeline focus
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Revenue forecasts • Trial milestones • Patent risk modeling